A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Part of paid clinical trials in Anchorage, Alaska.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT06101134
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- relatlimab+nivolumab — DRUGSpecified dose on specified days
- relatlimab+nivolumab+rHuPH20 — DRUGSpecified dose on specified days
- nivolumab — DRUGSpecified dose on specified days
- nivolumab+rHuPH20 — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.
Key Dates
- Start date
- Nov 6, 2023
- Status verified
- Mar 2026
- Primary completion
- Apr 10, 2025
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 100 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1: Metastatic Melanoma
- Experimental: Cohort 2: Resected Melanoma
Primary Outcome Measure
Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose [ Time Frame: Cycle 4 Day 1 (each cycle consist of 4 weeks) ]
Locations (9)
| Facility | City | State | ZIP |
|---|---|---|---|
| Local Institution - 0007 | Anchorage | Alaska | 99508-2974 |
| Local Institution - 0013 | Phoenix | Arizona | 85054-4502 |
| Local Institution - 0010 | San Francisco | California | 94115-3010 |
| Local Institution - 0034 | Atlanta | Georgia | 30342 |
| Local Institution - 0032 | Edgewood | Kentucky | 41017 |
| Local Institution - 0028 | Albuquerque | New Mexico | 87106 |
| Local Institution - 0037 | Edmonds | Washington | 98026-8032 |
| Local Institution - 0036 | Issaquah | Washington | 98026 |
| Local Institution - 0030 | Seattle | Washington | 98104 |
Related coverage on Hipa.ai
- Nivolumab: Melanoma Patients Prefer Subcutaneous Administration in Phase 2 TrialNivolumab · Apr 9, 2026 · ClinicalTrials.gov
Find similar trials in Anchorage, AK
By condition
By specialty
Related Studies
- A Phase I/II Trial of Vemurafenib and Metformin to Melanoma PatientsPHASE1/PHASE2 · Recruiting · University of Louisville · Louisville, Kentucky
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsPHASE2 · Recruiting · Vyriad, Inc. · Phoenix, Arizona